Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
Launched by HOFFMANN-LA ROCHE · Oct 30, 2024
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the genetic make-up of individuals who carry a specific mutation associated with Huntington Disease (HD). Researchers want to learn more about certain genetic variants, called single nucleotide polymorphisms (SNPs), that could be related to this condition. If you or a family member are between the ages of 25 and 60 and have been confirmed as a carrier of the HD gene mutation, you may be eligible to participate.
The study involves a single visit to a Huntington Disease clinic, where you will answer questions about your background and health history. At the end of the visit, a small blood sample will be taken for genetic testing. There are no specific health issues that would exclude you from participating, but you must be able to tolerate a blood draw. This study is currently looking for participants, and your involvement could help researchers better understand Huntington Disease and its genetic factors.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Have signed the Informed Consent Form (ICF)
- • Aged 25 to 60 years, inclusive, at the time of signing the ICF
- • Confirmation of Huntington Disease (HD) gene expansion mutation carrier status
- • Confirmation of Total Functional Capacity (TFC) ≥9 and Total Motor Score (TMS) \>6 within 12 months prior to signing the ICF
- • Ability to tolerate blood draws
- Exclusion Criteria:
- • None
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Tampa, Florida, United States
Iowa City, Iowa, United States
Boston, Massachusetts, United States
Westmead, New South Wales, Australia
Parkville, Victoria, Australia
Madrid, , Spain
Phoenix, Arizona, United States
London, , United Kingdom
Ulm, , Germany
Edmonton, Alberta, Canada
Wellington, , New Zealand
Cambridge, , United Kingdom
Christchurch, , New Zealand
Ulm, , Germany
Montreal, Quebec, Canada
Toronto, Ontario, Canada
Ciudad Autonoma Buenos Aires, , Argentina
Sacramento, California, United States
Englewood, Colorado, United States
Baltimore, Maryland, United States
Pittsburgh, Pennsylvania, United States
Burgos, , Spain
Birmingham, Alabama, United States
Westmead, New South Wales, Australia
Erlangen, , Germany
La Jolla, California, United States
Halifax, Nova Scotia, Canada
Torres Vedras, , Portugal
Caulfield South, New South Wales, Australia
Kirkland, Washington, United States
Berlin, , Germany
Bochum, , Germany
Gda?Sk, , Poland
Warszawa, , Poland
Birmingham, , United Kingdom
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported